Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2023-05-31 00:00:00 ET · period of report 2023-05-26 · accession 0001209191-23-033143 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-31 | 2023-05-26 | ORMP | Kidron Miriam | CSO, Dir | A - Grant | — | +53.5K | 468.2K | +13% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-26 | A | A | 53,500 | — | 468,166 | D | — | — | (F1) Restricted Stock Units ("RSUs") granted in April 2023 and vested upon achievement of certain performance conditions. The RSUs converted into Issuer's common stock on a one-for-one basis. |